Triclacetamol

Triclacetamol

SCHEMBL29385347

O=C(Nc1ccc(O)cc1)C(Cl)(Cl)Cl

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.63
ALDH1A1 P00352 4/20 0.63
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
MAPK1 P28482 2/20 0.63
HPGD P15428 2/20 0.63
HTT P42858 1/20 0.63
CYP1A1 P04798 2/20 0.54
PEPD P12955 1/20 0.54
CA12 O43570 1/20 0.54
BRD4 O60885 1/20 0.54
NR1I2 O75469 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
MB P02144 1/20 0.54
CA3 P07451 1/20 0.54
CYP3A4 P08684 1/20 0.54
RARG P13631 1/20 0.54
TSHR P16473 1/20 0.54
ALOX5AP P20292 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6933661 0.81 KMT2A (0.61) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL6928350 0.81 MEN1 (0.61) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL11422852 0.81 KMT2A (0.61) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL1764510 0.80 MAPT (0.85) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL13901181 0.80 MAPT (0.56) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL22485592 0.79 KMT2A (0.59) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL8828273 0.79 KMT2A (0.65) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL3549311 0.78 CA12 (0.59) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL1422823 0.78 L3MBTL1 (0.83) MAPTALDH1A1KMT2AMEN1MAPK1
SCHEMBL6929094 0.78 MAPT (0.58) MAPTALDH1A1KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed